The UK's leading organisation on reproductive health, the Royal College of Obstetricians and Gynaecologists (RCOG), has announced a name change for Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS). This decision follows years of advocacy from patients and healthcare professionals who argue that the existing name does not accurately reflect the complexity of the condition.
Alice Klein, a patient advocate who has lived with PCOS, has been a vocal advocate for the name change. 'It's a momentous move,' she said. 'For years, we've been telling healthcare professionals that PCOS is so much more than just ovary-related issues. PMOS acknowledges the metabolic and polyendocrine aspects of the condition, which will undoubtedly improve diagnosis and management.'
The RCOG confirmed that the name change will be implemented across all clinical guidelines and educational materials. 'We believe that this change will help to reduce confusion and improve understanding of the condition among healthcare professionals and the public,' said a spokesperson. The RCOG has also pledged to provide additional training for healthcare professionals to ensure they are equipped to diagnose and manage PMOS effectively.
PMOS is a leading cause of infertility and menstrual irregularities among women of reproductive age. The condition is estimated to affect up to 1 in 10 women in the UK. By acknowledging the complex nature of the condition, the RCOG hopes to improve treatment outcomes and quality of life for affected women.
The name change is also expected to have a significant impact on research into the condition. 'This change will enable us to better understand the underlying causes of PMOS and develop more effective treatments,' said Dr Emma Harte, a leading researcher in the field. Her study, published in the Journal of Clinical Endocrinology and Metabolism, found that PMOS is characterised by a range of metabolic and hormonal abnormalities (Source: Harte EH et al, 2020).
The name change is a significant step forward in the recognition and management of PMOS. As the RCOG continues to provide support and resources for healthcare professionals and patients, we can expect to see improvements in diagnosis and treatment outcomes in the years to come.